Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients

Yang Liu; Huan-Wei Liang; Xin-Bin Pan

doi:doi:10.18632/aging.204781

← Back

Research Paper Volume 15, Issue 11 pp 5066—5074

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients

Figure 5. Multivariate regression analysis of prognostic factors for EGFR-mutated non-small cell lung cancer patients receiving TKI therapy in the propensity-matched cohort. (A) Progression-free survival. (B) Overall survival. EGFR: Epidermal growth factor receptor. TKI: tyrosine kinase inhibitor. ECOG: Eastern Cooperative Oncology Group.